Gilles Nobécourt
Director/Board Member at Inotrem SA
Profile
Gilles Nobécourt is currently a Director at Complix NV, a Non-Executive Director at Crescendo Biologics Ltd., a Director at Complexa, Inc., a Director at Inotrem SA, a Director at Evommune, Inc., and a Partner at Andera Partners SCA.
He has previously worked as a Director at Calliditas Therapeutics Suisse SA, GlycoVaxyn AG, Covagen AG, Fondation Ophtalmologique Adolphe de Rothschild, GamaMabs Pharma SA, Parvulus Medical SAS, and Calliditas Therapeutics France SAS.
He has also served as a Director at Innociné Performance and as a Deputy General Manager at Rhone-Poulenc Rorer, Inc. Additionally, he has worked as a Field Officer at the United Nations High Commissioner for Refugees and as a Vice President-Public Affairs at Rhone-Poulenc Group.
Mr. Nobécourt holds an undergraduate degree from Sciences Po and a graduate degree from Stanford Graduate School of Business.
Gilles Nobécourt active positions
Companies | Position | Start |
---|---|---|
Andera Partners SCA
Andera Partners SCA Investment ManagersFinance Andera Partners SCA (Andera Partners) is a private equity firm founded in 2001 by Pierre-Michel Passy. The firm is headquartered in Paris, France. | Private Equity Investor | 29/10/2002 |
Complix NV
Complix NV Pharmaceuticals: MajorHealth Technology Complix NVengages in the development of biopharmaceutical company developing Alphabodies, a pipeline of transformative protein therapeutics. The Company is currently focusing its internal research and development activities on oncology and autoimmune diseases. Its therapeutic Alphabodies focuses on the treatment of autoimmune diseases, such as rheumatoid arthritis, psoriasis and multiple sclerosis, and infectious diseases, and viral diseases such as influenza, HIV, and RSV. The company was founded by Mark Vaeck and Ignace Lasters in 2008 and is headquartered in Diepenbeek, Belgium. | Director/Board Member | 25/06/2013 |
Inotrem SA
Inotrem SA BiotechnologyHealth Technology Inotrem SA specializes in the development of therapeutic approaches based on its proprietary TREM-1 platform. The firm focuses on the control of immune reactions in acute inflammatory diseases. The company was founded by Jean-Jacques Garaud, Marc Derive and Sebastien Gibot in 2013 and is headquartered in Paris, France. | Director/Board Member | - |
Crescendo Biologics Ltd.
Crescendo Biologics Ltd. Miscellaneous Commercial ServicesCommercial Services Crescendo Biologics Ltd. engages in the development of new medicines based on antibody fragment technology. Its products in pipeline in dermatology include CB001, a transformational Humabody-based topical biologic for psoriasis which combines exceptional activity against a validated target with a topical route of delivery to avoid systemic side effects. The firm?s oncology products in pipeline include Humabody Multi-Specific T-Cell Engagers, Humabody Antibody Drug Conjugates and Immune Checkpoint Inhibitors. The company was founded by Michael Anthony Romanos, David Rayll Brown and John Bradshaw on November 13, 2007 and is headquartered in Cambridge, the United Kingdom. | Director/Board Member | - |
Evommune, Inc.
Evommune, Inc. Miscellaneous Commercial ServicesCommercial Services Evommune, Inc. engages in the development of medicines for inflammatory diseases. The company was founded by Luis C. Pe?a, Eugene Andrew Bauer, and Hans Hofland in 2020 and is headquartered in Los Altos, CA. | Director/Board Member | - |
Former positions of Gilles Nobécourt
Companies | Position | End |
---|---|---|
GENKYOTEX SA. | Director/Board Member | 02/11/2020 |
Calliditas Therapeutics Suisse SA
Calliditas Therapeutics Suisse SA Pharmaceuticals: GenericHealth Technology Calliditas Therapeutics Suisse SA engages in the development of NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes, which amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company was founded Chihiro Yabe, Robert A. Clark, David Lambeth, and Karl-Heinz Krause in 2006 and is headquartered in Geneva, Switzerland. | Director/Board Member | 27/02/2017 |
Rhone-Poulenc Rorer, Inc.
Rhone-Poulenc Rorer, Inc. Pharmaceuticals: MajorHealth Technology Rhone-Poulenc Rorer, Inc. discovers, develops and markets human pharmaceuticals. It operates in all major markets of the world. The company is headquartered in Collegeville, PA. | Corporate Officer/Principal | 01/01/1999 |
Fondation Ophtalmologique Adolphe de Rothschild
Fondation Ophtalmologique Adolphe de Rothschild Hospital/Nursing ManagementHealth Services Fondation Ophtalmologique Adolphe de Rothschild is a specialized hospital in Paris, FR that focuses on treating all pathologies related to the head and neck for both adults and children. The hospital has a pharmacy that ensures the supply of medicines and medical devices. The hospital also has a clinical research service that serves as a one-stop-shop for investigators and industrial or academic partners. The hospital is supported by the Edmond de Rothschild Foundations, which offer a Medical Fellowship program to support talented and promising young practitioners in their hospital-university dynamic. The CEO of the French company is Julien Gottsmann. | Director/Board Member | - |
░░░░░░░░ ░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Training of Gilles Nobécourt
Sciences Po | Undergraduate Degree |
Stanford Graduate School of Business | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 17 |
---|---|
Calliditas Therapeutics Suisse SA
Calliditas Therapeutics Suisse SA Pharmaceuticals: GenericHealth Technology Calliditas Therapeutics Suisse SA engages in the development of NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes, which amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company was founded Chihiro Yabe, Robert A. Clark, David Lambeth, and Karl-Heinz Krause in 2006 and is headquartered in Geneva, Switzerland. | Health Technology |
Rhone-Poulenc Rorer, Inc.
Rhone-Poulenc Rorer, Inc. Pharmaceuticals: MajorHealth Technology Rhone-Poulenc Rorer, Inc. discovers, develops and markets human pharmaceuticals. It operates in all major markets of the world. The company is headquartered in Collegeville, PA. | Health Technology |
Andera Partners SCA
Andera Partners SCA Investment ManagersFinance Andera Partners SCA (Andera Partners) is a private equity firm founded in 2001 by Pierre-Michel Passy. The firm is headquartered in Paris, France. | Finance |
GlycoVaxyn AG
GlycoVaxyn AG BiotechnologyHealth Technology GlycoVaxyn AG developed and produced bioconjugate vaccines. The company was founded in 2004 and was headquartered in Schlieren, Switzerland. | Health Technology |
United Nations High Commissioner for Refugees
United Nations High Commissioner for Refugees Services to the Health IndustryHealth Services The United Nations High Commissioner for Refugees, also known as UNHCR, is an organization that is committed to protecting the rights of refugees, forcibly displaced communities, and stateless individuals. The non-profit company is based in Suisse, Switzerland. The Swiss company's mission is to save lives and provide assistance to those who have been forced to flee their homes due to conflict, persecution, or other forms of violence. | Health Services |
Covagen AG
Covagen AG BiotechnologyHealth Technology Covagen AG engages in the research in as well as development, production, and distribution of pharmaceutical and diagnostic products and technologies. The company was founded by Julian Bertschinger and Dragan Grabulovski in 2007 and is headquartered in Zug, Switzerland. | Health Technology |
Complix NV
Complix NV Pharmaceuticals: MajorHealth Technology Complix NVengages in the development of biopharmaceutical company developing Alphabodies, a pipeline of transformative protein therapeutics. The Company is currently focusing its internal research and development activities on oncology and autoimmune diseases. Its therapeutic Alphabodies focuses on the treatment of autoimmune diseases, such as rheumatoid arthritis, psoriasis and multiple sclerosis, and infectious diseases, and viral diseases such as influenza, HIV, and RSV. The company was founded by Mark Vaeck and Ignace Lasters in 2008 and is headquartered in Diepenbeek, Belgium. | Health Technology |
Crescendo Biologics Ltd.
Crescendo Biologics Ltd. Miscellaneous Commercial ServicesCommercial Services Crescendo Biologics Ltd. engages in the development of new medicines based on antibody fragment technology. Its products in pipeline in dermatology include CB001, a transformational Humabody-based topical biologic for psoriasis which combines exceptional activity against a validated target with a topical route of delivery to avoid systemic side effects. The firm?s oncology products in pipeline include Humabody Multi-Specific T-Cell Engagers, Humabody Antibody Drug Conjugates and Immune Checkpoint Inhibitors. The company was founded by Michael Anthony Romanos, David Rayll Brown and John Bradshaw on November 13, 2007 and is headquartered in Cambridge, the United Kingdom. | Commercial Services |
Complexa, Inc.
Complexa, Inc. Pharmaceuticals: MajorHealth Technology Complexa, Inc. operates as a biopharmaceutical company which engages on discovering and developing therapies for the treatment of severe and life-threatening fibrosis and inflammatory diseases. The firm focuses on two therapeutic areas: focal segmental glomerulosclerosis (FSGS) and pulmonary arterial hypertension (PAH), two rare diseases that can compromise the normal function of the kidney and the heart. The company was founded by Bruce A. Freeman, Raymond A. Miller, and Margaret M. Tarpey in 2008 and is headquartered in Berwyn, PA. | Health Technology |
Rhone-Poulenc Group | |
Fondation Ophtalmologique Adolphe de Rothschild
Fondation Ophtalmologique Adolphe de Rothschild Hospital/Nursing ManagementHealth Services Fondation Ophtalmologique Adolphe de Rothschild is a specialized hospital in Paris, FR that focuses on treating all pathologies related to the head and neck for both adults and children. The hospital has a pharmacy that ensures the supply of medicines and medical devices. The hospital also has a clinical research service that serves as a one-stop-shop for investigators and industrial or academic partners. The hospital is supported by the Edmond de Rothschild Foundations, which offer a Medical Fellowship program to support talented and promising young practitioners in their hospital-university dynamic. The CEO of the French company is Julien Gottsmann. | Health Services |
GamaMabs Pharma SA
GamaMabs Pharma SA Medical/Nursing ServicesHealth Services GamaMabs Pharma SA specializes in developing monoclonal antibodies. It offers research and development solutions for biopharmaceutical industry. The company was founded by Jean-Francois Prost and Stephane Degove in June 2013 and is headquartered in Toulouse, France. | Health Services |
Parvulus Medical SAS | Distribution Services |
Inotrem SA
Inotrem SA BiotechnologyHealth Technology Inotrem SA specializes in the development of therapeutic approaches based on its proprietary TREM-1 platform. The firm focuses on the control of immune reactions in acute inflammatory diseases. The company was founded by Jean-Jacques Garaud, Marc Derive and Sebastien Gibot in 2013 and is headquartered in Paris, France. | Health Technology |
Calliditas Therapeutics France SAS
Calliditas Therapeutics France SAS Pharmaceuticals: MajorHealth Technology Calliditas Therapeutics France SAS is a biopharmaceutical company, which engages in the NOX therapies. Its therapeutic approach is based on a selective inhibition of NOX enzymes that amplify multiple disease processes, such as fibrosis, inflammation, pain processing, cancer development, and eurodegeneration. The firm’s platform enables the identification of orally available small molecules that selectively inhibit specific NOX enzymes. The company was founded in 2006 and is headquartered in Saint-Julien-en-Genevois, France. | Health Technology |
Innociné Performance | |
Evommune, Inc.
Evommune, Inc. Miscellaneous Commercial ServicesCommercial Services Evommune, Inc. engages in the development of medicines for inflammatory diseases. The company was founded by Luis C. Pe?a, Eugene Andrew Bauer, and Hans Hofland in 2020 and is headquartered in Los Altos, CA. | Commercial Services |
- Stock Market
- Insiders
- Gilles Nobécourt